JR
Highly rated in
6
conditions

Dr. Julio Rosenstock

Dallas, TX
Highly rated in
6
conditions
Specialties:Endocrinology
Experience:48 Years
Clinical Trials:Currently Recruiting for 6 Trials
Highly rated in
6
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Julio Rosenstock's experience treating your condition:
About Dr. Julio Rosenstock

Julio Rosenstock is an Endocrinologist in Dallas, Texas. Rosenstock has been practicing medicine for over 48 years and is highly rated in 6 conditions, according to our data. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Low Blood Sugar, and Obesity. He is licensed to treat patients in Texas.

His clinical research consists of co-authoring 263 peer reviewed articles and participating in 30 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Julio Rosenstock it is best to call his office and ask if your insurance is accepted.

Call to see if your plan is accepted.
Locations
7777 Forest Ln, C685, Dallas, TX 75230
Background & Education
Graduate Institution
Other, 1975
Specialties
Endocrinology
Licenses
Internal Medicine in TX
Hospital Affiliations
Medical City Dallas
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes
Enrollment Status: Recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults With Type 2 Diabetes
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Recruiting
Publish Date: August 24, 2022
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Active, not recruiting
Publish Date: December 12, 2022
Intervention Type: Drug
Study Drugs: TirzepatideDulaglutide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Active, not recruiting
Publish Date: December 09, 2022
Intervention Type: Drug
Study Drugs: LY3209590Insulin Degludec
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drugs: TirzepatideInsulin LisproInsulin Glargine
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drugs: LY3437943Dulaglutide
Study Phase: Phase 2
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590Insulin Degludec
Study Phase: Phase 2
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: LY3502970Dulaglutide
Study Phase: Phase 2
A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Active, not recruiting
Publish Date: October 12, 2022
Intervention Type: Drug
Study Drug: LY3502970
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Active, not recruiting
Publish Date: May 11, 2022
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)
Enrollment Status: Active, not recruiting
Publish Date: April 19, 2022
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
Enrollment Status: Active, not recruiting
Publish Date: April 13, 2022
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)
Enrollment Status: Active, not recruiting
Publish Date: March 23, 2022
Intervention Type: Other, Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Enrollment Status: Completed
Publish Date: February 25, 2022
Intervention Type: Drug
Study Drugs: LY900014Insulin Glargine
Study Phase: Phase 3
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: TirzepatideInsulin Glargine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: TirzepatideSemaglutide
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Enrollment Status: Completed
Publish Date: March 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: March 15, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Three Doses of AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia
Enrollment Status: Completed
Publish Date: December 19, 2008
Intervention Type: Drug
Study Phase: Phase 2
View 24 Less Clinical Trials -
263 Total Publications
Findings for iGlarLixi vs BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
Journal: Diabetes, obesity & metabolism
Published: August 30, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
AG
Dr. Abhimanyu Garg
Endocrinology
Highly rated in
14
conditions
Endocrinology

Internal Medicine Subspecialties Clinic At West Campus Building 3

2001 Inwood Rd, 
Dallas, TX 
 7.9 mi

Abhimanyu Garg is an Endocrinologist in Dallas, Texas. Garg has been practicing medicine for over 42 years and is highly rated in 14 conditions, according to our data. His top areas of expertise are Congenital Generalized Lipodystrophy, Familial Partial Lipodystrophy, Gigantism, Familial Hypertriglyceridemia, and Gastric Bypass. He is licensed to treat patients in Texas. Garg is currently accepting new patients.

ZA
Dr. Zahid S. Ahmad
Endocrinology
Highly rated in
8
conditions
Endocrinology

Internal Medicine Subspecialties Clinic At West Campus Building 3

2001 Inwood Rd, 
Dallas, TX 
 7.9 mi

Zahid Ahmad is an Endocrinologist in Dallas, Texas. Ahmad has been practicing medicine for over 19 years and is highly rated in 8 conditions, according to our data. His top areas of expertise are Familial Hypercholesterolemia, Familial Hypertriglyceridemia, Apolipoprotein C2 Deficiency, and Familial Lipoprotein Lipase Deficiency. He is licensed to treat patients in Texas. Ahmad is currently accepting new patients.

IL
Dr. Ildiko Lingvay
Endocrinology
Highly rated in
7
conditions
Endocrinology

Internal Medicine Subspecialties Clinic

2001 Inwood Rd, 
Dallas, TX 
 7.9 mi

Ildiko Lingvay is an Endocrinologist in Dallas, Texas. Lingvay has been practicing medicine for over 25 years and is highly rated in 7 conditions, according to our data. Her top areas of expertise are Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Low Blood Sugar, Obesity, and Gastric Bypass. She is licensed to treat patients in Texas. Lingvay is currently accepting new patients.